| 1:54:55 PM - Tue, Dec 7th 2021 |
|
Novavax has applied for a vaccine license in South Korea.
November 17, 2021 news report from Novavax, Inc. states that Novavax, Inc., a biotechnology company that develops and sells next-generation vaccines for severe infectiousSLOTdiseases, and SK Biosciences Company, a biotechnology based in South Korea, has announced Announcement of submission of documents to the Ministry of Food and Drug Safety (MFDS) of South Korea to apply for a biological license (BLA).
For the COVID-19 vaccine developed by Novawax, NVX-CoV2373, a hybrid nanoparticle vaccine with Matrix-M™ accelerator, is the first fractional protein vaccine used for BLA in South Korea.
“Today's filing reflects BLA's request to approve the use of the COVID-19 vaccine. The world's first full And much progress is expected,” said Stanley C. Erk, Novavax's president and chief executive officer.
“Our partnership with SK Biosciences reinforces our shared commitment to making vaccines equally accessible worldwide. As we work together to deliver our COVID-19 vaccine, built on a proven and well-understood platform.”
|
